In a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology...
MGNX as a biotech company makes antibodies against certain cancers. The antibody is tagged to
chemotherapy molecules and then heads off looking for cancer cells to which it has a strong
affinity. So much for the science. MGNX just got upgraded and the new target is $ 16.00 about
25% upside. Biotech and healthcare are projected hot sectors this year.
On the...
Moderna Inc.’s stock soared 14% early Thursday to early Friday after the biotech company and partner Merck & Co. announced positive data from a trial of Moderna’s mRNA-4157 in combination with Merck’s blockbuster cancer drug Keytruda in patients with resected high-risk melanoma (stage III/IV).
The companies said that after about three years, the combination...
If you haven`t bought the dip:
then you should know that today BCTX BriaCell Announced 10% Buyback of its Common Shares and up to 10% of Listed Warrants!
My short term Price Target is 9.30usd.
GOVX GeoVax Labs is a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer.
GeoVax Labs will report Q1 2022 financial results on April 27.
Jason McCarthy from Maxim Group has a $10.00 price target for GOVX.
The stock is now $1.01.
Market Cap of only 7.23Mil.
This is a 4X upside potential short term stock in my opinion.
An "error" in previously released results sent Galera Therapeutics, Inc. (GRTX) stock price down by more than 70% in October.
Today GRTX was upgraded today by HC Wainwright to buy, 10usd price target and by BTIG Research to 15usd price target.
Have you bought it yesterday?
SESN received a preapproval for the dug, Vicineum, but not in its present form. and the market overreacted to it. sold at market prices. and the price went down to 0.86usd, its strongest support.
The FDA has determined that it cannot approve the BLA for Vicineum in its present form and has provided recommendations specific to additional clinical/statistical data...
BYSI BeyondSpring drug, plinabulin, increased overall survival and improved other measures of disease while staving off a dangerous side effect associated with Chemotherapy.
BeyondSpring is preparing to ask for plinabulin approval in the U.S. and China.
On 8/4/2021 J. Pantginis from HC Wainwright brokerage Upgraded BYSI BeyondSpring from Neutral to Buy giving...
Ultimovacs’ UV1 in combination with pembrolizumab shows 60% Objective Response Rate in advanced melanoma Phase I data
• UV1/pembrolizumab results in 30% complete responses plus 30% partial responses
• Good safety and tolerability profile supports use of UV1 in combination treatments
• Data to be presented at ASCO and abstract to be discussed in webcast on May...
Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company.
As of...
· Current Price – $0.0419
· Best Case Scenario PT over 1$
· Market Cap – $11 million
· Debt – 0
Halbert Corporation
Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the...
Why SELLAS Life Sciences Is Surging Premarket?
SELLAS Life Sciences is captivating investors thanks to its late-stage cancer vaccine
Thanks to some news in December in the biopharma space, SLS stock is racing higher. So what was that news? And what else do you need to know?
its leading candidate Galinpepimut-S is making its way through Phase 3.
This...
Oslo, 19 October 2020: Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today
announced five-year overall survival data from the Phase I trial evaluating UV1
as maintenance therapy in patients with non-small cell lung cancer. The results
confirm achievement of the primary endpoints of safety and tolerability and
indicate encouraging initial signals of long-term...
